Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Ready for the challenge? Let’s begin!
Question 1 of 4: What is the primary mechanism of action for NKT2152?
NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose of the trastuzumab biosimilar and offer a focused recap of intriguing data presented at this year’s ESMO Congress.
Read More
The FDA granted IBI363 fast track status for melanoma and approved a ready-to-use subcutaneous bortezomib for MM and MCL. We also cover new data highlighting the efficacy of lenvatinib/pembrolizumab in nccRCC, cost-effectiveness of TKIs for CML, and innovative immunotherapies for T-cell malignancies.
Read More